secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2026-05-11T20:05:49+00:00
Accession:  0001104659-26-058638
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent Q1 net loss $43.3M; cash $326.4M; Phase 3 firmonertinib data mid-2026
------------------------------------------------------------------------------

- Net loss of $43.3M for Q1 2026 versus $64.4M in Q1 2025; R&D expenses $37.6M (down 39% YoY).
- Cash and investments $326.4M as of March 31, 2026, expected to fund operations into 4Q 2027.
- Topline Phase 3 FURVENT data for firmonertinib in first-line EGFR exon 20 insertion NSCLC expected mid-2026.
- FDA IND clearance for ARR-002 (MUC16/NaPi2b dual-target tetravalent ADC) for ovarian/endometrial cancers; first patient dosing in 2H 2026.
- ARR-217 (CDH17 ADC) first patient dosed March 2026; dose escalation ongoing for gastrointestinal malignancies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/0001104659-26-058638-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/avbp-20260511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-058638

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer